• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed

    1/26/21 4:10:51 PM ET
    $EIDX
    Major Pharmaceuticals
    Health Care
    Get the next $EIDX alert in real time by email
    POS AM 1 d61969dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on January 26, 2021

    Registration No. 333-232999

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST–EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S–3

    REGISTRATION STATEMENT NO. 333-232999

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    EIDOS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-3733671

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. employer

    identification no.)

    101 Montgomery Street, Suite 2000

    San Francisco, CA 94104

    (415) 887-1471

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Neil Kumar

    Chief Executive Officer

    Eidos Therapeutics, Inc.

    101 Montgomery Street, Suite 2000

    San Francisco, CA 94104

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies of all communications, including all communications sent to the agent for service, should be sent to:

    Stephen F. Arcano, Esq.

    Thomas W. Greenberg, Esq.

    Skadden, Arps, Slate, Meagher & Flom LLP

    One Manhattan West

    New York, NY 10001

    (212) 735-3000

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement

     

     


    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

     

     

     


    EXPLANATORY NOTE — DEREGISTRATION OF UNSOLD SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”), filed by Eidos Therapeutics, Inc., a Delaware corporation (the “Registrant”), relates to the Registration Statement on Form S-3 (Registration Number 333-232999) filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”) on August 2, 2019, as amended by Amendment No. 1 thereto filed with the SEC on August 23, 2019 (as amended, the “Registration Statement”), pertaining to the registration of the securities described in the Registration Statement.

    On October 5, 2020, the Registrant, BridgeBio Pharma, Inc. (“BridgeBio”), Globe Merger Sub I, Inc. (“Merger Sub”) and Globe Merger Sub II, Inc. (“Merger Sub II”) entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the “Merger Agreement”), providing for, upon the terms and subject to the conditions contained therein, (i) the merger of Merger Sub with and into the Registrant (the “Initial Merger”), with the Registrant surviving the Initial Merger, and (ii) thereafter, the merger of the Registrant with and into Merger Sub II (the “Subsequent Merger” and, together with the Initial Merger, the “Mergers”), with Merger Sub II surviving as an indirect wholly owned subsidiary of BridgeBio. The Initial Merger became effective on January 26, 2021 (the effective time of the First Merger, the “Effective Time”). Shortly after the Effective Time, the Subsequent Merger became effective.

    Immediately prior to the Effective Time, (i) each option to purchase common stock, par value $0.001 per share, of the Registrant (“Common Stock”) (an “Option”) was converted into an option, on the same terms and conditions applicable to such Option immediately prior to the Effective Time, to purchase a specified number of shares of common stock of BridgeBio, calculated pursuant to the terms of the Merger Agreement, and (ii) each outstanding award of shares of Common Stock that is subject to forfeiture conditions (subject to certain exceptions) (each, an “Restricted Share Award”) was converted into an award covering a number of whole restricted shares of common stock of BridgeBio, calculated pursuant to the terms of the Merger Agreement, with any fractional shares being paid out to the holder of such Restricted Share Award in cash.

    At the Effective Time, each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than shares of Common Stock (i) owned by the Registrant as treasury stock, (ii) owned by the Registrant, BridgeBio, Merger Sub, Merger Sub II or any other direct or indirect wholly owned subsidiary of BridgeBio and, in each case, not held on behalf of third parties and (iii) shares of Common Stock that are subject to Restricted Share Awards) was converted into the right to receive, at the election of each of the Registrant’s stockholders, either (1) 1.85 shares of common stock of BridgeBio or (2) $73.26 in cash, subject to proration. In connection with the Mergers, the Registrant has terminated all offerings of the Registrant’s securities pursuant to the Registration Statement.

    In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of post-effective amendment, any of the securities registered pursuant to the Registration Statement that remain unsold at the termination of the offering, the Registrant hereby removes from registration all such securities registered but unsold under the Registration Statement, if any, as of the filing date of this Post-Effective Amendment. The Registration Statement is hereby amended to reflect the deregistration of such securities and to terminate the effectiveness of the Registration Statement.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment to the Registration Statement on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of San Francisco, State of California, on this 26th day of January, 2021.

     

    EIDOS THERAPEUTICS, INC.
    By:  

    /s/ Neil Kumar

     

    Neil Kumar

    Chief Executive Officer

    Get the next $EIDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EIDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EIDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: C Jonathan Fox gifted 500 units of Common Stock, decreasing ownership by 100% to 0 units

      4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)

      1/28/21 7:50:50 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Douglas Rohlen

      4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)

      1/28/21 7:39:25 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Franco Valle

      4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)

      1/28/21 7:22:38 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care

    $EIDX
    SEC Filings

    See more
    • SEC Form 15-12B filed

      15-12B - Eidos Therapeutics, Inc. (0001731831) (Filer)

      2/5/21 4:30:52 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed

      EFFECT - Eidos Therapeutics, Inc. (0001731831) (Filer)

      1/28/21 12:15:15 AM ET
      $EIDX
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)

      1/26/21 4:10:59 PM ET
      $EIDX
      Major Pharmaceuticals
      Health Care

    $EIDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

      REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se

      6/28/21 7:10:00 PM ET
      $IOVA
      $BBIO
      $EIDX
      $BMEA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

      –Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM) –New Drug Application (NDA) for infigratinib for the treatment of cholangiocarcinoma accepted by the U.S. Food and Drug Administration (FDA) under Priority Review designation and Real-Time Oncology Review (RTOR) pilot program, designed to expedite the delivery of safe and effective cancer treatments to patients –Initiated two new clinical trials since las

      2/25/21 7:30:00 AM ET
      $EIDX
      $BBIO
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

      PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders.  The merger reunites the teams at BridgeBio and Eidos and allows BridgeBio to deploy its full clinical and commercial infrastructure to support the development and global commercialization plans underway for Eidos’ acoramidis, a potential best-in-class therapy for patients with transthyretin (TTR) amyloidosis

      1/26/21 8:30:00 AM ET
      $EIDX
      $BBIO
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $EIDX
    Leadership Updates

    Live Leadership Updates

    See more
    • BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

      REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se

      6/28/21 7:10:00 PM ET
      $IOVA
      $BBIO
      $EIDX
      $BMEA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger

      PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s proposed merger with Eidos and each of the other proposals to be considered at both companies’ virtual special meetings to be held on January 19, 2021.  Under the proposed merger agreement, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right t

      1/4/21 7:30:00 AM ET
      $EIDX
      $BBIO
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations